Biological monitoring of occupational exposure to antineoplastic drugs in hospital settings.
BACKGROUND
In view of the evidence of cytotoxicity of chemotherapic antineoplastic drugs (AD), current guidelines recommend the evaluation of the health risks of hospital personnel exposed to these compounds. Biological monitoring is the main tool to evaluate all possible drug intake and measure workers' real risk.


OBJECTIVE
The aim of this study was to assess occupational exposure toAD in a large hospital in Northern Italy in order to verify the effectiveness of the structural and procedural improvements carried out over the last decade.


METHODS
Three biological monitoring campaigns were performed using LC-MS/MS analysis of cyclophosphamide (CP) and metotrexate (MTX) as biomarkers of internal dose in the urine of hospital workers. In the first two campaigns, 50 and 81 workers respectively were monitored during AD preparation operations. The last campaign, concerning AD administration activity, was performed after a centralized preparation unit had been set up. Two environmental monitoring campaigns were carried out as well, to complete AD exposure assessment.


RESULTS
During the first monitoring campaign we found positive urinary samples in all the wards studied (total positivity 36%), whereas in the second campaign 11% of the samples were positive and four departments showed negative results in all urine samples. The last campaign showed all urinary CP and MTX levels below the detection limit of the analytical method


CONCLUSIONS
Exposure of oncology ward nurses considerably decreased due to the centralization of AD preparation operations together with training and education of workers. The last biological monitoring results were reassuring; nevertheless, surface contamination still occurred and safety measures should be further improved in order to achieve the lowest reasonably possible contamination levels.
Unità Operativa di Medicina del Lavoro, Policlinico Sant'Orsola-Malpighi, Bologna. l.sabatini@unibo.it
Laura
L
Sabatini
Anna
A
Barbieri
V
V
Lodi
F S
FS
Violante
D000328:Adult; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000652:urine*; D003520:Cyclophosphamide / Q000493:pharmacokinetics / Q000652:urine*; D004784:Environmental Monitoring; D005260:Female; D006293:Health Promotion / Q000706:statistics & numerical data*; D006801:Humans; D019570:Inhalation Exposure / Q000032:analysis / Q000517:prevention & control; D007558:Italy; D008297:Male; D008727:Methotrexate / Q000493:pharmacokinetics / Q000652:urine*; D008875:Middle Aged; D009741:Nursing Staff, Hospital; D016273:Occupational Exposure / Q000032:analysis* / Q000517:prevention & control; D016522:Oncology Service, Hospital / Q000706:statistics & numerical data; D010362:Patients' Rooms / Q000706:statistics & numerical data; D010564:Personnel, Hospital; D010607:Pharmacy Service, Hospital / Q000706:statistics & numerical data; D011482:Protective Devices / Q000706:statistics & numerical data; D018570:Risk Assessment; D012869:Skin Absorption; D055815:Young Adult
D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D008727:Methotrexate